All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Magrolimab in TP53-mutated AML and MDS: What are the latest updates from EHA2022?

Jul 8, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

During the EHA2022 Congress, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked for the latest updates about magrolimab in TP53-mutated AML and MDS from EHA2022.

Magrolimab in TP53-mutated AML and MDS: What are the latest updates from EHA2022?

Daver discusses a study investigating magrolimab + azacitidine in two patient groups: (1) patients with frontline higher-risk MDS and (2) older patients with AML who are unfit for intensive chemotherapy. Daver discusses the mechanism of action of magrolimab and concludes by outlining efficacy, survival, and adverse effects seen in both study arms.